



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 15, 2021

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001.
Scrip Code: **524816**

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.
Scrip Code: **NATCOPHARM**

Dear Sir,

Sub: News Paper Publication for Un-audited Financial Results and 3rd Interim Dividend FY 2020-21
Ref: Intimation under regulation 30 of SEBI (LODR) Regulations, 2015

This is to inform you that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find attached the newspaper clippings of the advertisement published on February 12, 2021 in Business Standard (All Editions) and Nava Telangana, Hyderabad (Telugu Edition) on February 12, 2021 pertaining to consideration of Un-audited Finance Results and declaration of 3rd Interim Dividend and record date for the Financial Year 2020-21.

kindly take the same on record and acknowledge the receipt

Thanking you

Yours faithfully
For NATCO Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

Encl: As above



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034. Phone:040-23547532.

Email : investors@natcopharma.co.in CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2020

(All amounts in ₹ millions)

Sl. No.	Particulars	CONSOLIDATED					
		Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Accounting Year Ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	3,552	8,022	4,822	17,208	14,602	19,150
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	801	2,707	1,288	5,089	4,520	5,687
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	801	2,707	1,288	5,089	4,520	5,687
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	627	2,024	1,045	3,879	3,667	4,608
5	Total Comprehensive Income for the period attributable to owners of the parent	668	1,979	1,051	3,896	3,699	4,463
6	Paid-up equity share capital of ₹ 2 each	364	364	364	364	364	364
7	Other equity (Revaluation reserve ₹ Nil)						37,371
8	Earnings Per Share (in Rupees) per ₹ 2/-share (non-annualised)						
	1. Basic	3.44	11.12	5.75	21.30	20.16	25.33
	2. Diluted	3.43	11.09	5.73	21.25	20.11	25.26

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under:

(All amounts in ₹, millions)

Sl. No.	Particulars	STANDALONE					
		Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Accounting Year Ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
		(Unaudited)			(Unaudited)		(Audited)
1	Revenue from operations	3,309	4,789	4,477	13,420	13,701	17,902
2	Profit before tax	707	865	1,273	3,188	4,592	5,831
3	Net profit for the period/ year	547	709	1,036	2,523	3,735	4,745
4	Total comprehensive income	551	770	1,015	2,593	3,669	4,681

2 The above is an extract of the detailed format of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2020 is available on the stock exchange websites, www.nseindia.com, www.bseindia.com and on the Company's website www.natcopharma.co.in.

3 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February, 11, 2021.

4 The Board of Directors at their meeting held on February 11, 2021 have declared an interim dividend of ₹ 1 per equity share of ₹ 2 each.

Place: Hyderabad

Date: February 11, 2021

for and on behalf of Board of Directors

NATCO Pharma Limited

Sd/- V.C. Nannapaneni, Chairman & Managing Director

NATCO

NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034. Phone:040-23547532,
Email : investors@natcopharma.co.in CIN : L24230TG1981PLC003201 www.natcopharma.co.in

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2020

(All amounts in ₹ millions)

Sl. No.	Particulars	CONSOLIDATED					
		Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Accounting Year Ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
(Unaudited)			(Unaudited)			(Audited)	
1	Revenue from operations	3,552	8,022	4,822	17,208	14,602	19,150
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	801	2,707	1,288	5,089	4,520	5,687
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	801	2,707	1,288	5,089	4,520	5,687
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	627	2,024	1,045	3,879	3,667	4,608
5	Total Comprehensive Income for the period attributable to owners of the parent	668	1,979	1,051	3,896	3,699	4,463
6	Paid-up equity share capital of ₹ 2 each	364	364	364	364	364	364
7	Other equity (Revaluation reserve ₹ Nil)						37,371
8	Earnings Per Share (in Rupees) per ₹ 2/-share (non-annualised)						
	1. Basic	3.44	11.12	5.75	21.30	20.16	25.33
	2. Diluted	3.43	11.09	5.73	21.25	20.11	25.26

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under.

(All amounts in ₹ millions)

Sl. No.	Particulars	STANDALONE					
		Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Accounting Year Ended
		31/12/2020	30/09/2020	31/12/2019	31/12/2020	31/12/2019	31/03/2020
(Unaudited)			(Unaudited)			(Audited)	
1	Revenue from operations	3,309	4,789	4,477	13,420	13,701	17,902
2	Profit before tax	707	865	1,273	3,188	4,592	5,831
3	Net profit for the period/ year	547	709	1,036	2,523	3,735	4,745
4	Total comprehensive income	551	770	1,015	2,593	3,669	4,681

2 The above is an extract of the detailed format of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2020 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2020 is available on the stock exchange websites, www.nseindia.com, www.bseindia.com and on the Company's website www.natcopharma.co.in.

3 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February, 11, 2021.

4 The Board of Directors at their meeting held on February 11, 2021 have declared an interim dividend of ₹ 1 per equity share of ₹ 2 each.

Place: Hyderabad
Date: February 11, 2021

for and on behalf of Board of Directors
NATCO Pharma Limited
Sd/- V.C. Nannapaneni, Chairman & Managing Director



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad - 500 034.
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

NOTICE

DECLARATION OF INTERIM DIVIDEND AND RECORD DATE

The Company hereby informs that the Board of Directors at their meeting held on 11th February, 2021 declared an Interim Dividend of Rs. 1/- per equity Share of Rs. 2/- each of the Company. The Interim Dividend will be paid to the shareholders of the Company whose name appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on 23rd February, 2021, being the Record Date fixed for the purpose. The payment of said Interim dividend will be start from 3rd March, 2021.

Place : Hyderabad
Date : 11-02-2021

For NATCO Pharma Limited
Sd/- M. Adinarayana
Company Secretary & Vice President
(Legal & Corporate Affairs)

Nava Telangana 12/02/2021



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad - 500 034.
CIN : L24230TG1981PLC003201 www.natcopharma.co.in

NOTICE

DECLARATION OF INTERIM DIVIDEND AND RECORD DATE

The Company hereby informs that the Board of Directors at their meeting held on 11th February, 2021 declared an Interim Dividend of Rs. 1/- per equity Share of Rs. 2/- each of the Company. The Interim Dividend will be paid to the shareholders of the Company whose name appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on 23rd February, 2021, being the Record Date fixed for the purpose. The payment of said Interim dividend will be start from 3rd March, 2021.

Place : Hyderabad
Date : 11-02-2021

For NATCO Pharma Limited
Sd/- M. Adinarayana
Company Secretary & Vice President
(Legal & Corporate Affairs)

Business Standard 12/02/201